• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a complex of formula (II) consisting of at least 90% of a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers of formulas: (II-SSS) (II-RRR ) The present invention also relates to a process for the preparation and purification of said complex of formula (II), as well as a composition comprising said complex.
    公开号:FR3091873A1
    申请号:FR1900432
    申请日:2019-01-17
    公开日:2020-07-24
    发明作者:Soizic le Greneur；Alain Chenede；Martine Cerf；Myriam Petta；Emmanuelle Marais；Bruno Francois；Caroline Robic；Stephanie Louguet
    申请人:Guerbet SA；
    IPC主号:
    专利说明:

    [0001] The present invention relates to a new process for the preparation and purification of a complex of gadolinium and of a chelating ligand derived from PCTA, which makes it possible to obtain, preferentially, the stereoisomers of said complex which have physico- chemicals of particular interest for applications as a contrast agent in the field of medical imaging, in particular for Magnetic Resonance Imaging. The present invention also relates to the diastereoisomerically enriched complex as such, a composition comprising said complex, as well as a process for preparing the corresponding chelating ligand by decomplexing said complex, and the ligand as such.
    [0002] Many contrast agents based on lanthanide chelates (paramagnetic metal), in particular gadolinium (Gd), are known, described for example in US Pat. No. 4,647,447. These products are often grouped under the term GBCA (Gadolinium-based Contrast Agent, contrast products based on gadolinium). Several products are on the market, among which are macrocyclic chelates, such as meglumine gadoterate based on DOTA (1,4,7,10-tetraazacyclododecane-N,N',N",N'"-tetraacetic acid), gadobutrol based on DO3A-butrol, gadoteridol based on HPDO3A, as well as linear chelates, in particular based on DTPA (diethylenetriaminepentaacetic acid) or DTPA-BMA (ligand of gadodiamide).
    [0003] Other products, some of which are under development, represent a new generation of GBCAs. These are essentially macrocyclic chelate complexes, such as bicyclopolyazamacrocyclocarboxylic acid (EP 0 438 206) or PCTA derivatives (i.e. comprising at least the chemical structure of the 3,6 acid, 9,15-tetraazabicyclo[9,3,1]pentadeca-1(15),11,13-triene-3,6,9-triacetic), as described in document EP 1 931 673.
    [0004] The complexes of chelating ligands derived from PCTA described in document EP 1 931 673 have the particular advantage of being relatively easy to synthesize chemically and, moreover, of exhibiting a relaxivity superior to other GBCAs (relaxivity r 1 which can go up to 11-12 mM - 1 .s -1 in water) currently on the market, this relaxivity corresponding to the effectiveness of these products and therefore to their contrasting power.
    [0005] In the body, the chelates (or complexes) of lanthanide – and in particular of gadolinium – are in a situation of chemical equilibrium (characterized by its thermodynamic constant K therm ), which can lead to an undesired release of said lanthanide (see equation 1 below):
    [0006] (equation 1)
    [0007] Chemical balance of complexation between the chelate or ligand ( Ch ) and lanthanide (L not ) to lead to the complex Ch-L not .
    [0008] Since 2006, a pathology called NSF (Nephrogenic Systemic Fibrosis, systemic nephrogenic fibrosis or fibrogenic dermopathy), has been linked, at least in part, to the release of free gadolinium in the body. This disease led to an alert from health authorities regarding gadoline contrast agents marketed for certain categories of patients.
    [0009] Strategies have therefore been put in place to solve the complex problem of patient tolerance in a completely safe manner, and to limit, or even eliminate, the risk of unwanted lanthanide release after administration. This problem is all the more delicate to solve as the administration of contrast agents is often repeated, whether during diagnostic examinations, or for adjusting doses and monitoring the effectiveness of a therapeutic treatment.
    [0010] In addition, since 2014, a possible cerebral deposition of gadolinium has been mentioned after repeated administration of gadolinated products, more particularly linear gadolinium chelates, such a deposition having not been reported, or only slightly, with macrocyclic gadolinium chelates, such as Dotarem ® . Consequently, various countries have decided either to withdraw most of the linear chelates from the market, or to drastically limit their indication for use, taking into account their stability deemed insufficient.
    [0011] A first strategy for limiting the risk of lanthanide release in the body thus consists in opting for complexes which are distinguished by the highest possible thermodynamic and/or kinetic stability. Indeed, the more the complex is stable, the more the quantity of lanthanide released over time will be limited.
    [0012] Other lines of improvement in the tolerance of lanthanide chelates (in particular of gadolinium) are described in the prior art. Document US 5,876,695, dating back more than thirty years, reports for example formulations comprising, in addition to the lanthanide chelate, an additional complexing agent, intended to prevent an undesired in-vivo release of the lanthanide, by complexing the lanthanide (ion metallic Gd 3+ ) salted out. The additional chelating agent can be introduced into the formulation either in its free form or in the form of a weak complex, typically of calcium, sodium, zinc or magnesium. Although it may possibly be distinct from the constituent ligand of the active complex, it is nevertheless important that the complex which it forms with the released lanthanide be less stable than the active complex, so as to prevent a transligation reaction between the active complex and the additional chelate, which would in particular have the effect of totally consuming said additional ligand, which could therefore no longer trap the released lanthanide. This risk of consumption of the additional chelating agent by transligation is more pronounced when it is added in the free form than in the form of a calcium complex, for example.
    [0013] Thus, in the two strategies described above, it is important that the active complex be as stable as possible.
    [0014] However, the complexes of chelating ligands derived from PCTA comprising a structure of the pyclene type described in the document EP 1 931 673, while having good kinetic stability, generally have a lower thermodynamic constant than that of the complexes of the other macrocycles cyclene derivatives.
    [0015] This is in particular the case of the complex of formula (II) represented below:
    [0016] (II)
    [0017] Indeed, as described in particular in document WO 2014/174120, the thermodynamic equilibrium constant corresponding to the formation reaction of the complex of formula (II), also called the stability constant, is 10 14.9 (ie log (K therm ) = 14.9). For comparison, the stability constant of the gadolinium complex of 1, 4, 7, 10 tetra-azacyclododecane N, N', N'', N''' tetra-acetic acid (DOTA-Gd), is of 10 25.6 (ie log (K therm ) = 25.6).
    [0018] It should however be noted that the complex of formula (II) corresponds to several stereoisomers, in particular due to the presence of the three asymmetric carbon atoms located in position α on the side chains of the complex, with respect to the nitrogen atoms of the macrocycle on which said side chains are grafted. These three asymmetric carbons are marked with an asterisk (*) in the formula (II) shown above.
    [0019] Thus, the synthesis of the complex of formula (II) as described in document EP 1 931 673 leads to the production of a mixture of stereoisomers.
    [0020] The aminopropanediol groups of the side chains of the complex of formula (II) also contain an asymmetric carbon. However, in the rest of the description, the only source of stereoisomerism considered for a given side chain will be, for the sake of simplification, that corresponding to the asymmetric carbon bearing the carboxylate group, marked with an asterisk (*) in the formula (II ) shown above.
    [0021] Insofar as each of these 3 asymmetric carbons can be of absolute configuration R or S, the complex of formula (II) exists in the form of 8 families of stereoisomers, called hereinafter II-RRR, II-SSS, II- RRS, II-SSR, II-RSS, II-SRR, II-RSR and II-SRS. More precisely, according to the usual nomenclature in stereochemistry, the complex of formula (II) exists in the form of 8 families of diastereoisomers.
    [0022] The use of the term "family" is justified in that each of its families includes several stereoisomers, in particular due to the presence of an asymmetric carbon within the aminopropanediol group, as mentioned above.
    [0023] Nevertheless, insofar as, in the remainder of the description, the stereoisomerism linked to the asymmetric carbon of a given aminopropanediol group will not be considered, reference will be made indiscriminately to isomers, stereoisomers or even diastereoisomers II-RRR, II-SSS, II-RRS, II-SSR, II-RSS, II-SRR, II-RSR and II-SRS, without specifying that each corresponds to a family of stereoisomers.
    [0024] The inventors have succeeded in separating and identifying by high performance liquid chromatography (HPLC, more commonly referred to by the English acronym HPLC) and by ultra high performance liquid phase chromatography (UHCP, more commonly referred to by the acronym English UHPLC) 4 masses or groups of isomers of the complex of formula (II) obtained according to the method of the prior art, corresponding to 4 different elution peaks characterized by their retention time on the chromatogram, which will be called iso1, iso2, iso3 and iso4 in the following description. By implementing the process described in document EP 1 931 673, the respective contents of the iso1, iso2, iso3 and iso4 groups in the mixture obtained are as follows: 20%, 20%, 40% and 20%.
    [0025] They then discovered that these different groups of isomers had distinct physico-chemical properties, and determined that the group of isomers called iso4, which includes a mixture of the II-RRR and II-SSS isomers with the formulas (II-RRR ) and (II-SSS) represented below, proves to be the most advantageous as a contrast agent for medical imaging.
    [0026] (II-RRR)
    [0027] Thus, iso4 is distinguished, surprisingly, by a much greater thermodynamic stability than that of the mixture of diastereoisomers in the form of which the complex of formula (II) is obtained by implementing the process described in document EP 1 931 673. Indeed, its equilibrium thermodynamic constant K therm iso4 is equal to 10 18.7 (ie log (K therm iso4 ) = 18.7) this value having been determined by implementing the method in Pierrard et al. , Contrast Media Mol. Imaging , 2008, 3, 243-252 and Moreau et al. , Dalton Trans. , 2007, 1611-1620.
    [0028] Moreover, iso4 is the group of isomers which exhibits the best kinetic inertia (also called kinetic stability) among the four groups isolated by the inventors. Indeed, the inventors evaluated the kinetic inertia of the four groups of isomers by studying their kinetics of decomplexation in acidic aqueous solution (pH=1.2), at 37°C. The values of the half-life times (T 1/2 ) which were determined for each of the groups of isomers are indicated in table 1 below, the half-life time corresponding to the time after which 50 % of the quantity of complex initially present has been dissociated, according to the following decomplexation reaction (equation 2):
    [0029] (equation 2) Isomer groups T 1/2 (pH 1.2 – 37°C)Iso1 18 hoursIso2 6 hoursIso3 8 daysIso4 27 days
    [0030] Table 1: kinetics of decomplexation of groups of iso1 to iso4 isomers
    [0031] For comparison, gadobutrol or gadoterate, macrocyclic gadolinium complexes, exhibit a kinetic inertia of 18 hours and 4 days respectively under the same conditions, while linear gadolinium complexes such as gadodiamide or gadopentetate dissociate instantaneously.
    [0032] (équation 3)In addition, iso4 is more stable from a chemical point of view than iso3 in particular. The amide functions of the complex of formula (II) are indeed capable of being hydrolyzed. The hydrolysis reaction of an amide function (equation 3) results in the formation of a dicoupled impurity, which is accompanied by the release of 3-amino-1,2-propanediol. The inventors have studied the kinetics of the hydrolysis reaction of the complex of formula (II) in aqueous solution at pH 13, and observed that the amide functions of iso4 are more stable with respect to hydrolysis than those of iso3.(equation 3)
    [0033] With regard to the relaxivity of the different groups of isomers, that is to say their effectiveness as a contrast agent, the measurements carried out show a relatively equivalent contrasting power for the groups iso1, iso2 and iso4, and lower efficiency for iso3 (see Table 2). Isomer groups r1 20 MHz(mM -1 .s -1 ) r1 60 MHz(mM -1 .s -1 )Iso1 12.6 12.5Iso2 13.3 12.9Iso3 8.0 8.1Iso4 12.9 13.0
    [0034] Table 2: relaxivity of groups of iso1 to iso4 isomers at 37°C
    [0035] The inventors have succeeded in developing a new process for the preparation and purification of the complex of formula (II) making it possible to preferentially obtain the II-RRR and II-SSS diastereoisomers of said complex, which have particularly advantageous physicochemical properties. The process according to the invention comprises an isomeric enrichment step, by conversion of the least stable stereoisomers to the most stable stereoisomers, which, surprisingly, while being carried out on the intermediate hexaacid complex and not on the final complex , makes it possible to obtain the very majority of the most stable isomers of the complex of formula (II).
    [0036] The implementation of a process which makes it possible to obtain mainly the diastereoisomers of interest is undeniably advantageous compared to the alternative consisting in preparing the mixture of stereoisomers, in order to then isolate the target diastereoisomers using any technique of separation well known in the art. Indeed, in addition to the fact that it is easier to implement a process devoid of a step for separating diastereoisomers on an industrial scale, the absence of separation allows on the one hand a considerable saving of time, and , on the other hand, to improve the overall yield of the process, by limiting as far as possible the production of the unwanted diastereoisomers which would ultimately be eliminated.
    [0037] As indicated above, the process for preparing the complex of formula (II) developed by the inventors is based on a step of isomeric enrichment of the gadolinium complex of intermediate hexaacid of formula (I) represented below:
    [0038] (I)
    [0039] The complex of formula (I) corresponds to several stereoisomers, due to the presence of the three asymmetric carbon atoms located in the α position on the side chains of the complex, relative to the nitrogen atoms of the macrocycle on which the said side chains are grafted. . These three asymmetric carbons are marked with an asterisk (*) in the formula (I) shown above.
    [0040] Insofar as each of the 3 asymmetric carbons carrying a carboxylate function can be of absolute configuration R or S, the complex of formula (I) exists in the form of 8 stereoisomers, referred to below as I-RRR, I-SSS, I -RRS, I-SSR, I-RSS, I-SRR, I-RSR and I-SRS. More precisely, according to the usual nomenclature in stereochemistry, the complex of formula (I) exists in the form of 4 pairs of enantiomers, diastereoisomers between them.
    [0041] The inventors have succeeded in separating and identifying by high performance liquid chromatography (HPLC, more commonly referred to by the English acronym HPLC) and by ultra high performance liquid phase chromatography (UHCP, more commonly referred to by the acronym English UHPLC) 4 masses or groups of isomers of the complex of formula (I) obtained according to the method described in document EP 1 931 673, corresponding to 4 different elution peaks characterized by their retention time on the chromatogram, that the 'isoA, isoB, isoC and isoD will be called in the remainder of the description.
    [0042] IsoD crystallizes in water. X-ray diffraction analyzes enabled the inventors to determine the crystalline structure of this group of isomers, and thus to discover that it comprises the I-RRR and I-SSS diastereoisomers of the complex of formula (I), of formulas (I-RRR) and (I-SSS) shown below.
    [0043] (I-SSS)
    [0044] (I-RRR)
    [0045] It should be noted that the I-RRR and I-SSS diastereomers of the complex of formula (I) are enantiomers of each other.
    [0046] The isomeric enrichment step of the process of the invention aims to enrich the gadolinium complex with the intermediate hexaacid of formula (I) in isoD.
    [0047] The synthesis of the complex of formula (II) notably involves a conversion of the carboxylic acid functions of the intermediate hexaacid complex of formula (I) into an amide function. This amidation reaction does not modify the absolute configuration of the three asymmetric carbon atoms of the complex of formula (I).
    [0048] Thus, when the amidification reaction is carried out on the hexaacid complex of formula (I) enriched in isoD previously obtained, it makes it possible to obtain the complex of formula (II) enriched in iso4.
    [0049] Furthermore, the purification process developed by the inventors makes it possible, when it is implemented following the process for preparing the complex of formula (II) mentioned above, to obtain the complex of formula (II) with a profile optimized isomeric, but also a significantly improved impurity profile.
    [0050] This diastereoisomerically enriched and purified complex exhibiting improved stability can therefore be formulated with a free macrocyclic ligand, such as free DOTA, instead of a calcium complex of DOTA, the use of which was recommended in document WO 2014 /174120. The use of free DOTA has in particular an advantage from an industrial point of view, in that it makes it possible to eliminate a step of the formulation synthesis process as described in document WO 2014/174120, namely the addition of CaCl 2 .
    [0051] Complex of formula (II)
    [0052] The present invention therefore relates firstly to a complex of formula (II):
    [0053] (II)
    [0054] consisting of at least 80% of a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers of formulas:
    [0055] (II-SSS)
    [0056] (II-RRR)
    [0057] By "diastereoisomeric excess" is meant, in the context of the present invention, and with regard to the complex of formula (II), the fact that said complex is mainly present in the form of an isomer or group of isomers chosen from among the diastereoisomers II-RRR, II-SSS, II-RRS, II-SSR, II-RSS, II-SRR, II-RSR and II-SRS. Said diastereoisomeric excess is expressed as a percentage and corresponds to the quantity which the major isomer or group of isomers represents relative to the total quantity of the complex of formula (II). It is understood that this percentage can be both molar and mass, insofar as isomers have, by definition, the same molar mass.
    [0058] In a particular embodiment, the complex of formula (II) according to the invention has at least 85%, in particular at least 90%, in particular at least 92%, preferably at least 94%, advantageously at least 97%, more preferably at least 99% of the diastereoisomeric excess comprising the mixture of II-RRR and II-SSS isomers.
    [0059] Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of II-RRR and II-isomers. SSS.
    [0060] Advantageously, said diastereoisomeric excess consists of the mixture of isomers II-RRR and II-SSS.
    [0061] The term “mixture of II-RRR and II-SSS isomers” also covers, by extension, the case where only one of the isomers, whether II-RRR or II-SSS, is present.
    [0062] However, in a preferred embodiment, the II-RRR and II-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/45 and 45/55. Advantageously, the II-RRR and II-SSS isomers are present within the mixture in a 50/50 ratio.
    [0063] More particularly, the diastereoisomeric excess as defined above corresponds to peak 4 of the UHPLC trace (i.e. the fourth isomer mass in the order of elution and corresponding to iso4), characterized by a retention time of about 6.3 minutes, said trace being obtained by implementing the UHPLC method described below.
    [0064] By "approximately" is meant that the retention time is reported with an accuracy of +/- 5%.
    [0065] By "UHPLC trace" is meant, within the meaning of the present invention, the profile of the concentrations measured by the detector after passage and separation of a mixture of compounds (in this case isomers of a compound) on a phase stationary as a function of time for a given composition and eluent flow rate. The UHPLC trace consists of different peaks or peaks characteristic of the compound or mixture of compounds analyzed.
    [0066] UHPLC method:
    [0067] CORTECS® UPLC T3 column 150 x 2.1 mm - 1.6 µm from Waters,
    [0068] analysis conditions: Sample Aqueous solution of the complex of formula (II) at 2.0 mg/mLColumn temperature 40°CSample temperature Ambient temperature(20-25°C)Debit 0.3mL/mininjection volume 1µLUV detection 200nm
    [0069] mobile phase gradient (% v /v): Time (mins) Acetonitrile (100%) H 2 SO 4 (0.0005% v/v aqueous solution)0 1 993 5 9512 10 90
    [0070] Composition comprising the complex of formula (II)
    [0071] The present invention relates secondly to a composition comprising:
    [0072] the complex of formula (II) consisting of at least 80% of a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers, and
    [0073] a free macrocyclic ligand.
    [0074] In the present description, the terms “macrocyclic ligand” or “macrocyclic chelate” can be used interchangeably.
    [0075] In the context of the present invention, the term “macrocycle” denotes a cycle typically comprising at least 9 atoms, whether carbon atoms or heteroatoms, and the “macrocyclic ligand” or “macrocyclic chelate” is a polydentate ligand, at least bidentate.
    [0076] By "free macrocyclic ligand" is meant within the meaning of the present invention the macrocyclic ligand in free form, that is to say not complexed, in particular with metals - including lanthanides and actinides - or with cations alkaline earth metals such as calcium or magnesium. In particular, the free macrocyclic ligand is not in the form of a complex with gadolinium.
    [0077] In a preferred embodiment, the complex of formula (II) present in the composition of the invention has at least 85%, in particular at least 90%, in particular at least 92%, more particularly at least 94%, preferably at least 97%, advantageously at least 99%, of the diastereoisomeric excess comprising the mixture of II-RRR and II-SSS isomers.
    [0078] Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of II-RRR and II-isomers. SSS.
    [0079] Advantageously, said diastereoisomeric excess consists of the mixture of isomers II-RRR and II-SSS.
    [0080] The term “mixture of II-RRR and II-SSS isomers” also covers, by extension, the case where only one of the isomers, whether II-RRR or II-SSS, is present.
    [0081] However, in a preferred embodiment, the II-RRR and II-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/45 and 45/55. Advantageously, the II-RRR and II-SSS isomers are present within the mixture in a 50/50 ratio.
    [0082] In an advantageous embodiment, the composition according to the invention has a free gadolinium concentration of less than 1 ppm (m/v), preferably less than 0.5 ppm (m/v).
    [0083] In the present description, unless otherwise stated, the expressions “Gd”, “gadolinium” and “Gd 3+ ” are used interchangeably to designate the Gd 3+ ion. By extension, it can also be a source of free gadolinium, such as gadolinium chloride (GdCl 3 ) or gadolinium oxide (Gd 2 O 3 ).
    [0084] In the present invention, the term “free Gd” denotes the uncomplexed forms of gadolinium, and preferably available for complexation. This is typically the water-solubilized Gd 3+ ion. By extension, it can also be a source of free gadolinium, such as gadolinium chloride (GdCl 3 ) or gadolinium oxide (Gd 2 O 3 ).
    [0085] Gadolinium in the free form is typically measured by colorimetric assay, usually xylenol orange or Arsenazo (III). In the absence of a metal ion (such as gadolinium), these indicators have a specific color: at acidic pH, orange xylenol has a yellow color, while Arsenazo has a pink color. In the presence of gadolinium, their color turns purple.
    [0086] The visual determination of the color change of the solution makes it possible to verify the presence or absence of gadolinium in the solution.
    [0087] In addition, it is possible to quantitatively measure the free gadolinium present in the solution via a back assay, using for example EDTA as a “weak” chelate of Gadolinium. In such an assay, the color indicator is added until a violet color is obtained. Then EDTA, a gadolinium ligand is added to the mixture drop by drop. Since EDTA is a stronger complexing agent than the colored indicator, the gadolinium will change ligand and will leave the colored indicator to complex preferentially with EDTA. The colored indicator will therefore gradually return to its non-complexed form.
    [0088] When the amount of EDTA added equals the initial amount of free Gd, the color indicator is entirely in its free form and the solution "turns" yellow. The quantity of EDTA added being known, this makes it possible to know the initial quantity of free Gd in the solution to be assayed.
    [0089] These methods are well known to those skilled in the art, and described in particular by document Barge et al. ( Contrast Media and Molecular Imaging 1 , 2006, 184-188).
    [0090] These colorimetric methods are thus usually implemented on a solution whose pH is between 4 and 8. Indeed, outside these pH ranges, the accuracy of the measurement may be affected due to a modification (or even a removal) of the colored toning.
    [0091] Thus, if necessary, the pH of the sample to be assayed is adjusted to be between 4 and 8. In particular, if the pH of the sample is acidic, and in particular less than 4, the pH is advantageously adjusted by adding d a base, then the measurement of the free Gd is carried out on the sample at the adjusted pH.
    [0092] The composition according to the invention thus exhibits stability over time, that is to say that its composition remains in accordance with the specifications in terms of concentration of free gadolinium (in particular its concentration of free Gd remains less than 1 ppm (m / v)), over a period of at least 3 years, preferably at least 4 years or more preferably at least 5 years, in particular in terms of free paramagnetic metal content. According to ICH guidelines, an observation of this stability for 6 months at 40°C is considered a good indication of a stability of 3 years at 25°C.
    [0093] In a particular embodiment, the composition according to the invention has a concentration of between 0.01 and 1.5 mol.L -1 , preferably between 0.2 and 0.7 mol.L -1 , more preferably between 0.3 and 0.6 mol.L -1 in the complex of formula (II) described above.
    [0094] The complex of formula (II) is assayed by methods known to those skilled in the art. It can in particular be assayed after mineralization and assay of the total gadolinium present in the composition, by optical emission spectrometry (also called ICP-AES or ICP Atomic Emission Spectrometry).
    [0095] The content of complex of formula (II) allows this composition to have an optimal contrasting power while having a satisfactory viscosity. Indeed, below 0.01 mol.L -1 of complex of formula (II) described above, the performance as a contrast product is less satisfactory, and at a concentration greater than 1.5 mol.L -1 , the viscosity of this composition becomes too high for easy handling.
    [0096] In a particular embodiment, the composition according to the invention comprises between 0.002 and 0.4% mol/mol, in particular between 0.01 and 0.3% mol/mol, preferably between 0.02 and 0.2% mol/mol, more preferably between 0.05 and 0.15% mol/mol of free macrocyclic ligand with respect to the complex of formula (II).
    [0097] Advantageously, the macrocyclic ligand is selected from the group consisting of DOTA, NOTA, DO3A, BT-DO3A, HP-DO3A, PCTA, DOTA-GA and their derivatives.
    [0098] Preferably, it is DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid).
    [0099] The concentration of free DOTA in the composition is typically measured by a copper back assay, using for example copper sulphate as the copper ion source.
    [0100] In this method, well known to those skilled in the art, a solution is preferably used containing a known initial concentration Q 0 of copper sulphate, this concentration being greater than the quantity of free ligand in the solution. To this solution of copper sulphate is added the solution to be assayed, containing free DOTA in a quantity Q 1 to be determined. DOTA is a very good copper complexing agent: the formation of a DOTA-copper complex is therefore observed.
    [0101] A return assay of the copper remaining free in the solution is then advantageously carried out by potentiometry. To do this, EDTA is for example added to the mixture drop by drop. EDTA will complex free copper in solution without decomplexing DOTA-copper, because DOTA is a stronger complexing agent than EDTA. When the quantity of EDTA added Q 2 is equal to the quantity of free copper in solution, a sudden drop in the potential of the solution is observed.
    [0102] Knowing the initial quantity Q 0 of copper and the quantity of added EDTA Q 2 , the subtraction of these two values Q 0 – Q 2 gives the quantity of free DOTA in the solution to be assayed Q 1 .
    [0103] Alternatively, HPLC methods can be used, in particular the HILIC LC-UV method.
    [0104] These measurement methods (in particular the potentiometric methods) are implemented on solutions whose pH is advantageously between 4 and 8. Thus, if necessary, the pH of the sample to be assayed is adjusted to be between 4 and 8. In particular, if the pH of the sample is acidic, and in particular less than 4, the pH is advantageously adjusted by adding a base such as meglumine, then the measurement of the free DOTA is carried out on the sample at the pH adjusted.
    [0105] Preferably, the proportions specified in the present invention and in particular above are proportions before sterilization of the composition.
    [0106] Advantageously, the pH of the composition is between 4.5 and 8.5, preferably between 5 and 8, advantageously between 6 and 8, in particular between 6.5 and 8. These pH ranges make it possible in particular to limit the appearance of certain impurities and promote the complexation of the paramagnetic metal ion M.
    [0107] In particular, the composition according to the invention can be buffered, that is to say it can also comprise a buffer chosen from the buffers for use established for the pH range 5 to 8 and preferably from the buffers lactate, tartrate, malate, maleate, succinate, ascorbate, carbonate, Tris (Tris(hydroxymethyl)aminomethane), HEPES (2-[4-(2-Hydroxyethyl)-1-piperazine]ethanesulfonic acid), MES (acid 2-morpholino ethanesulphonic) and mixtures thereof, and preferably a buffer chosen from Tris, lactate, tartrate, carbonate buffers, MES and mixtures thereof. Advantageously, the composition according to the invention comprises the Tris buffer.
    [0108] The composition that is the subject of the invention is preferably sterile.
    [0109] Process for the preparation of the complex of formula (II)
    [0110] The present invention further relates to a process for preparing the complex of formula (II) comprising the following successive steps:
    [0111] at. Complexation of the hexaacid of formula (III) below:
    [0112] (III)
    [0113] with gadolinium to obtain the hexaacid gadolinium complex of formula (I) as defined previously,
    [0114] b. Isomerization by heating of the hexaacid gadolinium complex of formula (I) in an aqueous solution at a pH of between 2 and 4, to obtain a diastereoisomerically enriched complex consisting of at least 80% of a diastereoisomeric excess comprising a mixture of isomers I-RRR and I-SSS of said hexaacid gadolinium complex of formula (I), and
    [0115] vs. Formation, from the diastereoisomerically enriched complex obtained in step b), of the complex of formula (II), by reaction with 3-amino-1,2-propanediol.
    [0116] In the present description, unless otherwise stated, the expressions “Gd”, “gadolinium” and “Gd 3+ ” are used interchangeably to designate the Gd 3+ ion. By extension, it can also be a source of free gadolinium, such as gadolinium chloride (GdCl 3 ) or gadolinium oxide (Gd 2 O 3 ).
    [0117] In the present invention, the term “free Gd” denotes the uncomplexed forms of gadolinium, and preferably available for complexation. This is typically the water-solubilized Gd 3+ ion. By extension, it can also be a source of free gadolinium, such as gadolinium chloride (GdCl 3 ) or gadolinium oxide.
    [0118] Step a)
    [0119] During this step, a complexation reaction takes place between the hexaacid of formula (III) and gadolinium, which makes it possible to obtain the gadolinium complex of hexaacid of formula (I) as defined above.
    [0120] According to a particular embodiment, step a) comprises the reaction between the hexaacid of formula (III) and a source of free Gd in water.
    [0121] In a preferred embodiment, the source of free Gd is GdCl 3 or Gd 2 O 3 , preferably Gd 2 O 3 .
    [0122] Preferably, the reagents used in step a), that is to say the source of gadolinium (typically gadolinium oxide), the hexaacid of formula (III) and water, are the purest. possible, especially with regard to metallic impurities.
    [0123] Thus, the source of gadolinium will advantageously be gadolinium oxide, preferably with a purity greater than 99.99%, and even more preferably greater than 99.999%.
    [0124] The water used in the process preferably comprises less than 50 ppm calcium, more preferably less than 20 ppm, and most preferably less than 15 ppm calcium. Generally, the water used in the process is deionized water, or water for injection (ppi water).
    [0125] Advantageously, the quantities of the reagents (the hexaacid of formula (III) and the gadolinium) used during this stage a) correspond to, or are close to, stoichiometric proportions, as dictated by the equation-balance of the reaction of complexation taking place during this step.
    [0126] By “close to stoichiometric proportions”, is meant that the difference between the molar proportions in which the reactants are introduced and the stoichiometric proportions is less than 15%, in particular less than 10%, preferably less than 8%.
    [0127] The gadolinium can in particular be introduced in a slight excess with respect to the stoichiometric proportions. The ratio of the amount of material introduced in gadolinium to the amount of material introduced in hexaacid of formula (III) is then greater than 1, but typically less than 1.15, in particular less than 1.10, advantageously less than 1.08 . In other words, the amount of gadolinium introduced is greater than 1 equivalent (eq.), but typically less than 1.15 eq., in particular less than 1.10 eq., advantageously less than 1.08 eq., relative to the amount of hexaacid of formula (III) introduced, which for its part corresponds to 1 equivalent. In the preferred embodiment according to which the source of free gadolinium is Gd 2 O 3 , the quantity of Gd 2 O 3 introduced is then typically greater than 0.5 eq., but less than 0.575 eq., in particular less than 0, 55 eq., advantageously less than 0.54 eq., relative to the quantity of hexaacid of formula (III) introduced (1 eq.).
    [0128] According to a particular embodiment, step a) comprises the following successive steps:
    [0129] a1) Preparation of an aqueous solution of hexaacid of formula (III), and
    [0130] a2) Addition, to the aqueous solution obtained in step a1), of a source of free gadolinium.
    [0131] In this embodiment, the content of hexaacid of formula (III) in the aqueous solution prepared during step a1) is typically between 10% and 60%, in particular between 15% and 45%, preferably between 20% and 35%, advantageously between 25% and 35%, even more advantageously between 25% and 30% by weight relative to the total weight of the aqueous solution.
    [0132] Preferably, steps a) and b) are carried out according to a one-pot embodiment, that is to say in the same reactor and without an intermediate step of isolation or purification.
    [0133] Thus, in this preferred embodiment, the hexaacid gadolinium complex of formula (I) formed during step a) is directly subjected to step b) of isomerization, without being isolated or purified, and in the same reactor as that used for step a).
    [0134] Step b)
    [0135] The gadolinium complex of hexaacid of formula (I) formed by the complexation reaction between the hexaacid of formula (III) and gadolinium during step a) is initially obtained in the form of a mixture of diastereoisomers .
    [0136] Step b) aims to enrich the mixture of diastereoisomers in the I-RRR isomers and I-SSS, to obtain the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) consisting of at least 85%, in particular of at least 90%, in particular of at least 95%, preferably of at least least 97%, advantageously at least 98%, more advantageously at least 99% of a diastereoisomeric excess comprising the mixture of I-RRR and I-SSS isomers.
    [0137] By "diastereoisomeric excess" is meant, in the context of the present invention, and with regard to the complex of gadolinium of hexaacid of formula (I), the fact that said complex is mainly present in the form of an isomer or group of isomers chosen from the diastereoisomers I-RRR, I-SSS, I-RRS, I-SSR, I-RSS, I-SRR, I-RSR and I-SRS. Said diastereoisomeric excess is expressed as a percentage, and corresponds to the quantity represented by the major isomer or group of isomers relative to the total quantity of the gadolinium complex of hexaacid of formula (I). It is understood that this percentage can be both molar and mass, insofar as isomers have, by definition, the same molar mass.
    [0138] Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of I-RRR and I- SSS.
    [0139] Advantageously, said diastereoisomeric excess consists of the mixture of isomers I-RRR and I-SSS.
    [0140] The inventors have in fact discovered that factors such as the pH and the temperature of the solution of gadolinium complex of hexaacid of formula (I) obtained at the end of step a) have an influence on the ratio in which the various isomers of the complex of formula (I) are present within the mixture of diastereoisomers. Over time, the mixture tends to enrich itself in a group of isomers including the isomers which are, surprisingly, the most thermodynamically and chemically stable, in this case the I-RRR and I-SSS isomers.
    [0141] The term “mixture of I-RRR and I-SSS isomers” also covers, by extension, the case where only one of the isomers, whether I-RRR or I-SSS, is present.
    [0142] However, in a preferred embodiment, the I-RRR and I-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/45 and 45/55. Advantageously, the mixture of I-RRR/I-SSS isomers is a racemic mixture (50/50).
    [0143] Step b) of isomerization of the hexaacid gadolinium complex of formula (I) in an aqueous solution is typically carried out at a pH of between 2 and 4, in particular between 2 and 3, advantageously between 2.2 and 2, 8.
    [0144] The pH is preferably adjusted with an acid, preferably an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid, for example with hydrochloric acid .
    [0145] Step b) is typically carried out at a temperature between 80°C and 130°C, in particular between 90°C and 125°C, preferably between 98°C and 122°C, advantageously between 100°C and 120°C. C, typically for a period of between 10h and 72h, in particular between 10h and 60h, advantageously between 12h and 48h.
    [0146] In a particular embodiment, the aqueous solution of step b) comprises acetic acid. Step b) is then advantageously carried out at a temperature of between 100°C and 120°C, in particular between 110°C and 118°C, typically for a period of between 12 h and 48 h, in particular between 20 h and 30 h, in particular between 24h and 26h.
    [0147] The acetic acid is preferably added before heating the solution of gadolinium hexaacid complex of formula (I) obtained during step a) in an amount such that the acetic acid content is between 25% and 75%, in particular between 40% and 50% by mass relative to the mass of hexaacid of formula (III) used during step a).
    [0148] When the aqueous solution is heated to a temperature advantageously between 100°C and 120°C, typically between 110°C and 118°C, acetic acid is added as the water evaporates, so as to maintain a constant volume of solution.
    [0149] According to a preferred embodiment, at the end of step b), the diastereoisomerically enriched complex is isolated by crystallization, preferably by crystallization by seeding.
    [0150] In this embodiment, step b) comprises the following successive steps:
    [0151] b1) Isomerization by heating of the hexaacid gadolinium complex of formula (I) in an aqueous solution at pH between 2 and 4, to obtain a diastereoisomerically enriched complex consisting of at least 80% of the diastereoisomeric excess comprising the mixture I-RRR and I-SSS isomers of said hexaacid gadolinium complex of formula (I), and
    [0152] b2) Isolation by crystallization of said diastereoisomerically enriched complex, preferably by crystallization by seeding.
    [0153] Step b2) of crystallization aims on the one hand to eliminate any impurities present in the aqueous solution, which may result from previous steps, so as to obtain a product of greater purity, discolored, in the form of crystals, and on the other hand to continue the diastereoisomeric enrichment of the gadolinium complex of hexaacid of formula (I), so as to obtain a diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers of said complex greater than that obtained at the result of step b1). Indeed, the I-RRR and I-SSS isomers of the hexaacid complex of formula (I) crystallize in water. On the other hand, the hexaacid gadolinium complex of formula (I) not enriched in said isomers does not crystallize.
    [0154] Step b2) is advantageously carried out at a temperature between 10°C and 70°C, in particular between 30°C and 65°C, in particular between 35°C and 60°C.
    [0155] According to a variant, after lowering the temperature of the aqueous solution, so that the latter is within the ranges indicated above, the crystallization process is induced by seeding. "Crystallization by seed", also called "crystallization by seed", includes the introduction into the reactor in which the crystallization is carried out (also called crystallizer) of a known quantity of crystals, called "seed" or "starter". This reduces the crystallization time. Seed crystallization is well known to those skilled in the art. In the process according to the invention, the seeding by use of a primer, in this case crystals of gadolinium complex of hexaacid of formula (I) diastereoisomerically enriched added in the aqueous solution of the diastereoisomerically enriched complex whose temperature has been previously lowered, makes it possible to obtain nucleation, and thus to initiate crystallization. The duration of the crystallization by seeding is advantageously between 2 h and 20 h, preferably between 6 h and 18 h, typically, it is 16 h.
    [0156] The diastereoisomerically enriched hexaacid gadolinium complex crystals of formula (I) are then typically isolated by filtration and drying, using any technique well known to those skilled in the art.
    [0157] Advantageously, the degree of purity of the diastereoisomerically enriched gadolinium hexaacid complex of formula (I) isolated at the end of step b2) is greater than 95%, in particular greater than 98%, advantageously greater than 99%, said degree of purity being expressed as a mass percentage of the complex of formula (I) relative to the total mass obtained at the end of step b2).
    [0158] In a particular embodiment, the diastereoisomerically enriched complex from step b) isolated by crystallization is again purified by recrystallization, to obtain a diastereoisomerically enriched and purified complex.
    [0159] In this embodiment, step b) comprises, in addition to the successive steps b1) and b2) previously described, a step b3) of purification by recrystallization of the isolated diastereoisomerically enriched gadolinium hexaacid complex of formula (I).
    [0160] Step b3) of recrystallization aims, like step b2) of crystallization, on the one hand, to obtain a product of greater purity, and, on the other hand, to continue the diastereoisomeric enrichment of the hexaacid gadolinium complex of formula (I), so as to obtain a diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers of said complex greater than that obtained at the end of step b2).
    [0161] Step b3) typically comprises the following successive sub-steps:
    [0162] suspending the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) isolated during step b2) in aqueous solution, preferably in water,
    [0163] solubilization of said complex by heating to a temperature advantageously between 80° C. and 120° C., for example at 100° C.,
    [0164] recrystallization, preferably by seeding, at a temperature advantageously between 10°C and 90°C, in particular between 20°C and 87°C, in particular between 55°C and 85°C, typically for a period of between 2 hours and 8 p.m., in particular between 6 a.m. and 6 p.m., and
    [0165] isolation of crystals of gadolinium complex of hexaacid of formula (I) diastereoisomerically enriched and purified, for example by filtration and drying.
    [0166] The degree of purity of the purified diastereoisomerically enriched gadolinium hexaacid complex of formula (I) isolated at the end of step b3) is typically greater than 98%, in particular greater than 99%, advantageously greater than 99.5% , said degree of purity being expressed as a mass percentage of the complex of formula (I) relative to the total mass obtained at the end of step b2).
    [0167] In another embodiment, the diastereoisomerically enriched complex of step b) is further enriched by selective decomplexation of the diastereoisomers of the complex of formula (I) other than the I-RRR and I-SSS diastereoisomers, ie by selective decomplexation of the diastereoisomers I-RSS, I-SRR, I-RSR, I-SRS, I-RRS and I-SSR.
    [0168] In this embodiment, step b) comprises, in addition to the successive steps b1) and b2) previously described, a step b4) of selective decomplexation of the diastereoisomers of the complex of formula (I) other than the diastereoisomers I-RRR and I -SSS. In this variant, step b) can also comprise step b3) previously described, said step b3) being implemented between steps b2) and b4), or after step b4).
    [0169] Step b4) of selective decomplexation aims to continue the diastereoisomeric enrichment of the complex of gadolinium with the hexaacid of formula (I), so as to obtain a diastereoisomeric excess comprising the mixture of the I-RRR and I-SSS isomers of said higher complex to that obtained at the end of step b2) or at the end of step b3), when the latter is implemented prior to step b4).
    [0170] Step b4) typically comprises the following successive sub-steps:
    [0171] suspending the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) isolated during step b2) or during step b3) in water,
    [0172] addition of a base, for example soda,
    [0173] heating to a temperature advantageously between 30°C and 60°C, in particular between 35°C and 55°C, for example at 40°C, typically for a period of between 2h and 20h, in particular between 10h and 18h,
    [0174] cooling to a temperature advantageously between 10°C and 30°C, for example to 30°C, and
    [0175] isolation of the diastereoisomerically enriched and purified hexaacid gadolinium complex of formula (I), for example by filtration and drying.
    [0176] In a preferred embodiment, the diastereoisomerically enriched complex obtained at the end of step b) according to any one of the variants described above has at least 85%, in particular at least 90%, in particular at least 95 %, preferably at least 97%, advantageously at least 98%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of I-RRR and I-SSS isomers.
    [0177] Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of I-RRR and I- SSS.
    [0178] Advantageously, said diastereoisomeric excess consists of the mixture of I-RRR and I-SSS isomers.
    [0179] The term “mixture of I-RRR and I-SSS isomers” also covers, by extension, the case where only one of the isomers, whether I-RRR or I-SSS, is present.
    [0180] However, in a preferred embodiment, the I-RRR and I-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/45 and 45/55. Advantageously, the mixture of I-RRR/I-SSS isomers is a racemic mixture (50/50).
    [0181] Step c)
    [0182] Step c) aims to form the complex of formula (II) from its precursor, the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) obtained during step b).
    [0183] During this step, the three carboxylic acid functions of the hexaacid complex of formula (I) carried by the carbon atoms located in the γ position on the side chains of the complex, relative to the nitrogen atoms of the macrocycle on which the said side chains, are converted into amide functions, by amidation reaction with 3-amino-1,2-propanediol, in racemic or enantiomerically pure form, preferably in racemic form.
    [0184] This amidation reaction does not modify the absolute configuration of the three asymmetric carbon atoms located in position α on the side chains, with respect to the nitrogen atoms of the macrocycle on which the said side chains are grafted. Consequently, step c) makes it possible to obtain the complex of formula (II) with a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers identical to the diastereoisomeric excess comprising a mixture of I-RRR isomers and I-SSS with which is obtained the diastereoisomerically enriched hexaacid gadolinium complex of formula (I) obtained at the end of step b), which is at least 80%.
    [0185] In a preferred embodiment, the complex of formula (II) obtained at the end of step c) has at least 85%, in particular at least 90%, in particular at least 92%, preferably at least 94% , advantageously at least 97%, more advantageously at least 99% of the diastereoisomeric excess comprising the mixture of II-RRR and II-SSS isomers.
    [0186] Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of II-RRR and II-isomers. SSS.
    [0187] Advantageously, said diastereoisomeric excess consists of the mixture of II-RRR and II-SSS isomers.
    [0188] The term “mixture of II-RRR and II-SSS isomers” also covers, by extension, the case where only one of the isomers, whether II-RRR or II-SSS, is present.
    [0189] However, in a preferred embodiment, the II-RRR and II-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/45 and 45/55. Advantageously, the II-RRR and II-SSS isomers are present within the mixture in a 50/50 ratio.
    [0190] The amidation reaction can be carried out according to all the methods well known to those skilled in the art, in particular in the presence of an agent which activates carboxylic acid functions and/or in acid catalysis.
    [0191] It can in particular be carried out according to the methods described in patent EP 1 931 673, in particular in paragraph [0027] of this patent.
    [0192] In a particular embodiment, step c) comprises the activation of the carboxylic acid functions (-COOH) of the hexaacid complex of formula (I) carried by the carbon atoms located in position γ on the side chains of the complex, by relative to the nitrogen atoms of the macrocycle on which the said side chains are grafted, in the form of derivative functions comprising a carbonyl group (C=O), which are such that the carbon atom of the carbonyl group is more electrophilic than the carbon atom of the carbonyl group of the carboxylic acid functions. Thus, according to this particular embodiment, said carboxylic acid functions can in particular be activated in the form of ester functions, acyl chlorides, acid anhydrides, or in any activated form capable of leading to an amide bond. The activated forms capable of leading to an amide bond are well known to those skilled in the art and can for example be obtained by all the methods known in peptide chemistry for creating a peptide bond. Examples of such methods are given in the publication Synthesis of peptides and peptidomimetics vol.E22a, p425-588, Houben-Weyl et al ., Goodman Editor, Thieme-Stuttgart-New York (2004), and, among these examples, can be mentioned in particular the methods of activating carboxylic acids via an azide (acyl azide), for example by the action of a reagent such as diphenylphosphoryl azide (commonly designated by the English acronym DPPA), the the use of carbodiimides alone or in the presence of catalysts (for example N-hydroxysuccinimide and its derivatives), the use of a carbonyldiimidazole (1,1'-carbonyldiimidazole, CDI), the use of phosphonium salts such as benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate (commonly referred to by the English acronym BOP) or uroniums such as 2-(1H-benzotriazol-1-yl)-1,1,3 hexafluorophosphate, 3-tetramethyluronium (commonly referred to by the English acronym HBTU).
    [0193] Preferably, step c) comprises the activation of the carboxylic acid functions (-COOH) mentioned above in the form of ester, acyl chloride or acid anhydride functions.
    [0194] By “ester function”, is meant, within the meaning of the present invention, a —C(O)O— group. It may in particular be a —C(O)OR 1 group, in which R 1 corresponds to a (C 1 -C 6 )alkyl group.
    [0195] By “(C 1 -C 6 )alkyl” group is meant, within the meaning of the present invention, a saturated hydrocarbon chain, linear or branched, comprising 1 to 6, preferably 1 to 4, carbon atoms. By way of example, mention may be made of the methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert -butyl, pentyl or even hexyl groups.
    [0196] By “acyl chloride function”, also called “acid chloride function”, is meant within the meaning of the present invention a —CO—Cl group.
    [0197] By “acid anhydride function” is meant, within the meaning of the present invention, a —CO—O—CO— group. It may in particular be a —CO—O—CO—R 2 group, in which R 2 corresponds to a (C 1 -C 6 )alkyl group.
    [0198] The conversion reactions of a carboxylic acid function into an ester, acyl chloride or acid anhydride function are well known to those skilled in the art, who can implement them according to any usual method with which they are familiar.
    [0199] The complex of formula (II) is then obtained by aminolysis of the carboxylic acid functions activated in the form of ester functions, acyl chlorides or acid anhydrides, by reaction with 3-amino-1,2-propanediol, in the form racemic or enantiomerically pure, preferably in racemic form.
    [0200] Preferably, the steps of activating the carboxylic acid functions and of aminolysis are carried out according to a one-pot embodiment, that is to say in the same reactor and without step intermediate for isolating or purifying the intermediate comprising the carboxylic acid functions activated in the form of ester, acyl chloride or acid anhydride functions.
    [0201] According to a particular embodiment, step c) comprises the following successive steps:
    [0202] c1) formation of an activated complex of formula (VII),
    [0203] (VII)
    [0204] in which Y represents a chlorine atom, an -OR 1 or -OC(O)-R 2 group, with R 1 and R 2 corresponding, independently of each other, to a group (C 1 -C 6 )alkyl, and
    [0205] c2) aminolysis of the activated complex of formula (VII) with 3-amino-1,2-propanediol.
    [0206] As will clearly appear to those skilled in the art, the formation reaction of the activated complex of formula (VII) does not modify the absolute configuration of the three asymmetric carbon atoms located in position α on the side chains, with respect to the atoms of macrocycle nitrogen on which said side chains are grafted. Consequently, step c1) makes it possible to obtain the activated complex of formula (VII) with a diastereoisomeric excess comprising a mixture of the VII-RRR and VII-SSS isomers, of formulas (VII-RRR) and (VII-SSS) represented below, identical to the diastereoisomeric excess comprising a mixture of I-RRR and I-SSS isomers with which is obtained the complex of gadolinium of hexaacid of formula (I) diastereoisomerically enriched obtained at the end of step b), which is at least 80%.
    [0207] (VII-SSS),
    [0208] (VII-RRR).
    [0209] In the case where Y represents a chlorine atom, step c1) is typically carried out by reaction between the diastereoisomerically enriched gadolinium hexaacid complex of formula (I) obtained during step b) and thionyl chloride ( SOCl 2 ).
    [0210] In the case where Y represents an -OC(O)-CH 3 group, step c1) is typically carried out by reaction between the diastereoisomerically enriched gadolinium complex of hexaacid of formula (I) obtained during step b) and acetyl chloride.
    [0211] In an advantageous embodiment, step c) comprises the activation of the carboxylic acid functions (-COOH) mentioned above in the form of ester functions.
    [0212] According to this embodiment, step c) may more particularly comprise the following successive steps:
    [0213] c1) formation of a triester of formula (VIII),
    [0214] (VIII)
    [0215] in which R 1 represents a (C 1 -C 6 )alkyl group, and
    [0216] c2) aminolysis of the triester of formula (VIII) with 3-amino-1,2-propanediol.
    [0217] Step c1) is typically carried out in the alcohol of formula R 1 OH, which plays both the role of solvent and reagent, in the presence of an acid such as hydrochloric acid.
    [0218] Step c2) is also typically carried out in the alcohol of formula R 1 OH, in the presence of an acid such as hydrochloric acid.
    [0219] Thus, steps c1) and c2) can easily be implemented according to a one-pot embodiment. Advantageously, the triester of formula (VII) is not isolated between steps c1) and c2).
    [0220] In a preferred embodiment, step c) comprises the following successive steps:
    [0221] c1) formation of a methyl triester of formula (IV),
    [0222] (IV)
    [0223] in particular by reaction in methanol in the presence of an acid such as hydrochloric acid, and
    [0224] c2) aminolysis of the methyl triester of formula (IV) with 3-amino-1,2-propanediol, in particular in methanol in the presence of an acid such as hydrochloric acid.
    [0225] Advantageously, the methyl triester of formula (IV) is not isolated between steps c1) and c2).
    [0226] The present invention encompasses all the combinations of the particular, advantageous or preferred embodiments described above in connection with each step of the method.
    [0227] Preparation of the hexaacid of formula (III)
    [0228] The hexaacid of formula (III), which occurs during step a) of the process for preparing the complex of formula (II) according to the invention, can be prepared according to all the methods already known and in particular according to the methods described in patent EP 1 931 673.
    [0229] However, according to a preferred embodiment, the hexaacid of formula (III) is obtained by alkylation of the pyclene of formula (V):
    [0230] (V)
    [0231] with a compound of formula R 3 OOC-CHG p -(CH 2 ) 2 -COOR 4 (IX),
    [0232] in which :
    [0233] R 3 and R 4 represent, independently of each other, a (C 4 -C 6 )alkyl group, such as a butyl, isobutyl, sec-butyl, tert -butyl, pentyl or hexyl group, and
    [0234] G p represents a leaving group such as a tosylate or triflate group, or a halogen atom, preferably a bromine atom,
    [0235] to obtain the hexaester of formula (X)
    [0236] (X)
    [0237] followed by a hydrolysis step, leading to said hexaacid of formula (III).
    [0238] In a preferred embodiment, R 3 and R 4 are identical.
    [0239] According to an advantageous embodiment, the hexaacid of formula (III) is obtained by alkylation of the pyclene of formula (V):
    [0240] (V)
    [0241] with dibutyl 2-bromoglutarate, to obtain the butyl hexaester of formula (VI):
    [0242] (VI)
    [0243] followed by a hydrolysis step, leading to said hexaacid of formula (III).
    [0244] The dibutyl 2-bromoglutarate used is in racemic or enantiomerically pure form, preferably in racemic form.
    [0245] The alkylation reaction is typically carried out in a polar solvent, preferably in water, in particular in deionized water, advantageously in the presence of a base such as potassium or sodium carbonate.
    [0246] The reaction is advantageously carried out at a temperature between 40° C. and 80° C., typically between 50° C. and 70° C., in particular between 55° C. and 60° C., for a period of between 5 h and 20 h, in particular between 8 a.m. and 3 p.m.
    [0247] The hydrolysis step is advantageously carried out in the presence of an acid or a base, advantageously a base such as sodium hydroxide. The hydrolysis solvent can be water, an alcohol such as ethanol, or a water/alcohol mixture. This step is advantageously carried out at a temperature of between 40°C and 80°C, typically between 40°C and 70°C, in particular between 50°C and 60°C, typically for a period of between 10h and 30h, in particular between 3 p.m. and 10 p.m.
    [0248] Method of purification of the complex of formula (II)
    [0249] The present invention further relates to a process for purifying the complex of formula (II) below:
    [0250] (II)
    [0251] with at least 80% of a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers of formula:
    [0252] (II-SSS)
    [0253] (II-RRR)
    [0254] including:
    [0255] 1) the combination of the following 2 steps:
    [0256] 1b) passing over ion exchange resin(s), and
    [0257] 1c) ultrafiltration of said complex, and
    [0258] 2) isolation of the purified complex thus obtained in solid form.
    [0259] Advantageously, said complex of formula (II) having at least 80%, preferentially at least 85%, in particular at least 90%, in particular at least 95%, more particularly at least 97%, preferably at least 98%, advantageously at least at least 99%, of a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers was previously obtained according to the preparation process described above.
    [0260] In a preferred embodiment, the diastereoisomerically enriched complex on which the purification process is implemented has at least 85%, in particular at least 90%, in particular at least 92%, preferably at least 94%, advantageously at least 97%, more preferably at least 99% of the diastereoisomeric excess comprising the mixture of II-RRR and II-SSS isomers.
    [0261] Preferably, said diastereoisomeric excess consists of at least 70%, in particular of at least 80%, advantageously of at least 90%, preferably of at least 95% of the mixture of II-RRR and II-isomers. SSS.
    [0262] Advantageously, said diastereoisomeric excess consists of the mixture of isomers II-RRR and II-SSS.
    [0263] The term “mixture of II-RRR and II-SSS isomers” also covers, by extension, the case where only one of the isomers, whether II-RRR or II-SSS, is present.
    [0264] However, in a preferred embodiment, the II-RRR and II-SSS isomers are present within said mixture in a ratio of between 65/35 and 35/65, in particular between 60/40 and 40/60, in particular between 55/45 and 45/55. Advantageously, the II-RRR and II-SSS isomers are present within the mixture in a 50/50 ratio.
    [0265] Combination of stars type s 1 b ) and 1c)
    [0266] Steps 1b) and 1c) aim to purify the complex of formula (II) by eliminating any impurities present due to its method of obtaining.
    [0267] Said impurities may in particular comprise 3-amino-1,2-propanediol and/or a dicoupled impurity.
    [0268] Indeed, 3-amino-1,2-propanediol may be present in the final product obtained during the implementation of a process for the preparation of the complex of formula (II), typically when the complex of formula (II) is obtained by amidation from the complex of formula (I) and 3-amino-1,2-propanediol. This is in particular the case of the process for preparing the complex of formula (II) according to the invention. As detailed above, the amidation reaction may include the activation of the three carboxylic acid functions carried by the carbon atoms located in the γ position on the side chains of the complex of formula (I), relative to the nitrogen atoms of the macrocycle onto which said side chains are grafted, followed by aminolysis of the carboxylic acid functions activated by reaction with 3-amino-1,2-propanediol. 3-Amino-1,2-propanediol is then advantageously used in excess, so as to ensure good conversion into amide functions of the three activated carboxylic acid functions.
    [0269] By “dicoupled impurity”, is meant a complex of formula (II-dc-a), (II-dc-b), (II-dc-c) represented below or a mixture thereof:
    [0270] (II-dc-a)
    [0271] (II-dc-b)
    [0272] (II-dc-c)
    [0273] The dicoupled impurity may in particular result from the hydrolysis reaction of an amide function of the complex of formula (II). It can also result from incomplete activation of the carboxylic acid functions of the complex of formula (I) (activation of two functions out of the three) or from incomplete aminolysis of the activated carboxylic acid functions (aminolysis of two functions out of the three), when the process for preparing the complex of formula (II) implements such steps. This is in particular the case of the process for preparing the complex of formula (II) according to the invention.
    [0274] Step 1b) corresponds to passage over ion exchange resin(s) of the complex of formula (II) diastereoisomerically enriched as described above.
    [0275] By "ion exchange resin" is meant, within the meaning of the present invention, a solid material generally in the form of beads composed of a polymer matrix on which are grafted positively (anionic resin) or negatively charged functional groups. (cationic resin), which will make it possible to respectively trap anions or cations by adsorption. The adsorption of anions or cations on the resin proceeds by ion exchange between the counter-ions of the functional groups initially present in order to ensure the electroneutrality of the resin, and the anions or cations intended to be trapped.
    [0276] Step 1b) comprises bringing an aqueous solution of the diastereoisomerically enriched complex of formula (II) into contact with a strong anionic resin. The water used is preferably purified water.
    [0277] Said strong anionic resin typically comprises, as exchange functional groups, ammonium groups (N(RR'R'') + , where R, R' and R'' are identical or different (C 1 -C 6 )alkyl groups) . Mention may in particular be made of the Amberlite ® FPA900 resin marketed by Dow Chemical, advantageously in the HO − form.
    [0278] Passing through a strong anionic resin eliminates, at least in part, the dicoupled impurities.
    [0279] Step 1b) may further comprise bringing an aqueous solution of the diastereoisomerically enriched complex of formula (II) into contact with a weak cationic resin. The water used is preferably purified water.
    [0280] Said weak cationic resin typically comprises, as exchange functional groups, carboxylate groups (CO 2 - ). Mention may in particular be made of the IMAC® HP336 resin marketed by Dow Chemical, advantageously in the H + form.
    [0281] Passage over a weak cationic resin makes it possible to eliminate, at least in part, the 3-amino-1,2-propanediol.
    [0282] Step 1c) corresponds to the ultrafiltration of the complex of formula (II) diastereoisomerically enriched as described previously.
    [0283] By "ultrafiltration" is meant, in the present invention, a method of filtration through a semi-permeable, mesoporous membrane, the pores of which generally have a diameter of between 1 and 100 nm, in particular between 2 and 50 nm, in particular between 10 and 50 nm (mesopores), under the effect of forces such as pressure gradients, typically between 1 and 10 bars, and possibly of concentration. It is therefore a process of membrane separation by which particles in solution or in suspension whose size is greater than that of the pores are retained by the membrane, and separated from the liquid mixture which contained them.
    [0284] In the context of the purification process according to the invention, ultrafiltration is particularly advantageous for eliminating endotoxins.
    [0285] Advantageously, the ultrafiltration membrane used during step 1c) has a cut-off threshold below 100 kD, in particular below 50 kD, in particular below 25 kD, typically, a cut-off threshold of 10 kD.
    [0286] Preferably, during step 1c), the transmembrane pressure is between 1 and 5 bars, in particular between 2.25 and 3.25 bars.
    [0287] In a particular embodiment, steps 1b) and 1c) are also combined with a step 1a) of nanofiltration.
    [0288] The term "nanofiltration" is intended to denote, in the present invention, a method of filtration through a semi-permeable, porous membrane, the pores of which generally have a diameter of between 0.1 and 100 nm, in particular between 0 1 and 20 nm, in particular between 1 and 10 nm, under the effect of forces such as pressure gradients, typically between 1 and 50 bars, and optionally of concentration. It is therefore a process of membrane separation by which particles in solution or in suspension whose size is greater than that of the pores are retained by the membrane, and separated from the liquid mixture which contained them.
    [0289] Stage 1a) of nanofiltration makes it possible to eliminate most of the 3-amino-1,2-propanediol (possibly in the form of salt or derivatives, in particular the acetamide derivative) in excess.
    [0290] Advantageously, the nanofiltration membrane used during step 1a) has a cut-off threshold of less than 1 kD, in particular of less than 500 Daltons, in particular of less than 300 Daltons, typically a cut-off of 200 Daltons.
    [0291] Preferably, during step 1a), the transmembrane pressure is between 10 and 40 bars, in particular between 2 and 30 bars.
    [0292] In particular, the temperature of the solution of the complex of formula (II) subjected to ultrafiltration during step 1a) is between 20 and 40°C, in particular between 25 and 35°C.
    [0293] In an alternative of this particular embodiment, step 1b) does not include bringing an aqueous solution of the diastereoisomerically enriched complex of formula (II) into contact with a weak cationic resin.
    [0294] In a particular embodiment, steps 1a) when the latter is present, 1b and 1c are carried out in this order.
    [0295] 2nd step)
    [0296] Step 2) aims to isolate in solid form the purified complex of formula (II) obtained at the end of the combination of steps 1b) and 1c), and optionally further combined in step 1a).
    [0297] This step of isolation in solid form can be carried out according to any method well known to those skilled in the art, in particular by atomization, by precipitation, by freeze-drying or by centrifugation, advantageously by atomization.
    [0298] In a preferred embodiment, step 2) includes atomization.
    [0299] The air inlet temperature in the atomizer is then typically between 150°C and 180°C, in particular between 160°C and 175°C, advantageously between 165°C and 170°C. The outlet temperature is itself typically between 90°C and 120°C, preferably between 105°C and 110°C.
    [0300] Advantageously, the degree of purity of the complex of formula (II) diastereoisomerically enriched in the mixture of II-RRR and II-SSS isomers purified and isolated at the end of step 2) is greater than 95%, in particular greater than 97%, preferably greater than 97.5%, more preferably greater than 98%, advantageously greater than 99%, said degree of purity being expressed as a mass percentage of the complex of formula (II) relative to the total mass obtained at the from step 2).
    [0301] The present invention also relates to the complex of formula (II) diastereoisomerically enriched and purified, capable of being obtained according to the purification process of the invention.
    [0302] Preferably, the complex of formula (II) included in the composition according to the invention described above is the complex of formula (II) diastereoisomerically enriched and purified, capable of being obtained according to the purification process of the invention.
    [0303] EXAMPLES
    [0304] The examples given below are presented by way of non-limiting illustration of the invention.
    [0305] Separation of iso1, iso2, iso3 and iso4 isomer groups of the complex of formula (II) by UHPLC
    [0306] A UHPLC device consisting of a pumping system, an injector, a chromatographic column, a UV detector and a data station is used. The chromatographic column used is a 150×2.1 mm −1.6 μm UHPLC column (CORTEX® UPLC T3 column from Waters).
    [0307] Movable phase:
    [0308] Route A: 100% acetonitrile and Route B: aqueous solution of H 2 SO 4 (96%) at 0.0005% v/v
    [0309] Preparation of test solutions:
    [0310] Solution of the complex of formula (II) at 2 mg/mL in purified water
    [0311] Analysis conditions: Column temperature 40°CSample temperature Ambient temperature (20-25°C)Debit 0.3ml/mininjection volume 1µlUV detection 200nmAnalysis time 20 mins
    [0312] gradient: Time % Acne % H2SO4 0.0005 %0 1 993 5 9512 10 9015 25 7516 1 9920 1 99
    [0313] 4 main peaks are obtained. Peak 4 of the UHPLC trace, i.e. iso4, corresponds to a retention time of 6.3 minutes.
    [0314] Preparation of the butyl hexaester of formula (VI)
    [0315] In a reactor, 184 kg (570 moles) of dibutyl 2-bromoglutarate and 89 kg (644 moles) of potassium carbonate are mixed and heated to 55-60°C. An aqueous solution of 29.4 kg (143 moles) of pyclene in 24 kg of water is added to the previous preparation. The reaction mixture is maintained at 55-60° C. and then heated under reflux for about ten hours. After reaction, the medium is cooled, diluted with 155 kg of toluene and then washed with 300 liters of water. The butyl hexaester is extracted in the aqueous phase with 175 kg (1340 moles) of phosphoric acid (75%). It is then washed 3 times with 150 kg of toluene. The butyl hexaester is reextracted in the toluene phase by dilution with 145 kg of toluene and 165 kg of water followed by basification with 30% (m/m) soda to reach a pH of 5-5.5. The lower aqueous phase is removed. The butyl hexaester is obtained by concentration to dryness under vacuum at 60° C. with a yield of approximately 85%.
    [0316] Preparation of the hexaacid of formula (III)
    [0317] In a reactor, 113 kg (121 moles) of butyl hexaester are loaded as well as 8 kg of ethanol. The medium is brought to 55+/-5° C. then 161 kg (1207.5 moles) of 30% (m/m) sodium hydroxide are poured in over 3 hours. The reaction mixture is maintained at this temperature for about twenty hours. The butanol is then removed by decantation from the reaction medium. The hexaacid of formula (III) obtained in the form of sodium salt is diluted with water to obtain an aqueous solution of approximately 10% (m/m). This solution is treated on an acid cationic resin. The hexaacid of formula (III) in aqueous solution is obtained with a yield of approximately 90% and a purity of 95%.
    [0318] Preparation of the hexaacid gadolinium complex of formula (I)
    [0319] Experimental protocol
    [0320] Complexation and isomerization
    [0321] Without acetic acid
    [0322] 418 kg (117 kg of pure hexaacid of formula (III) / 196 mol) of an aqueous solution of hexaacid of formula (III) at 28% by weight are loaded into a reactor. The pH of the solution is adjusted to 2.7 by adding hydrochloric acid, then 37 kg (103.2 moles) of gadolinium oxide are added. The reaction medium is heated at 100-102°C for 48 hours to achieve the expected isomeric distribution of the hexaacid of formula (III).
    [0323] With acetic acid
    [0324] Gadolinium oxide (0.525 molar eq.) is suspended in a solution of hexaacid of formula (III) at 28.1% by mass.
    [0325] The 99-100% acetic acid (50% by weight/pure hexaacid of formula (III)) is poured onto the medium at room temperature.
    [0326] The medium is heated to reflux and then distilled to 113°C by mass, recharging the medium with acetic acid as the water is eliminated. Arrived at 113°C, we add the sufficient quantity of acetic acid in order to arrive at the starting volume.
    [0327] The medium is maintained at 113° C. overnight.
    [0328] Crystallization, Recrystallization
    [0329] Crystallization
    [0330] The hexaacid gadolinium complex of formula (I) in solution is cooled to 40° C., the primer is added, and the mixture is left in contact for at least 2 hours. It is then isolated by filtration at 40°C and washed with reverse osmosis water.
    [0331] Recrystallization
    [0332] 180 kg of the hexaacid gadolinium complex of formula (I) obtained previously (dry extract at approximately 72%) are suspended in 390 kg of water. The medium is heated to 100°C to dissolve the product, then cooled to 80°C to be primed by adding a little primer. After cooling to room temperature, the hexaacid gadolinium complex of formula (I) is isolated by filtration and drying.
    [0333] Selective decomplexation
    [0334] The dry product is loaded into the reactor with osmosis water/ at 20°C. The mass of water added is equal to twice the mass of gadolinium hexaacid complex of theoretical formula (I). 30.5% (m/m) sodium hydroxide (6.5 eq) is poured onto the medium at 20°C. The medium is left in contact at 50°C at the end of the addition of NaOH for 4:00 p.m. The medium is cooled to 25° C. and the product filtered through a bed of Clarcel.
    [0335] Content of the mixture of diastereoisomers I-RRR and I-SSS
    [0336] The ratio in which the different isomers of the complex of formula (I) are present within the mixture of diastereoisomers depends on the conditions under which the complexation and isomerization steps are carried out, as shown in Table 3 below. pH Temperature Content of hexaacid of formula (III) Duration diastereoisomeric excess in the mixture I-RRR and I-SSS 5.7 80°C 40% 3h 19%3.5 90°C 50% 10am 49%3.0 101°C 40% 10am 68%2.7 101°C 28% 48h 98.04%
    [0337] Table 3: content of the I-RRR and I-SSS mixture according to the complexation / isomerization confitions
    [0338] The additional stages of recrystallization and selective decomplexation make it possible to increase the diastereoisomeric excess in the I-RRR and I-SSS mixture (see table 4). After the 1st crystallization After recrystallization After selective decomplexation diastereoisomeric excess in the mixture I-RRR and I-SSS 98.04% 99.12% 99.75%
    [0339] Table 4: content of the I-RRR and I-SSS mixture after crystallization / recrystallization / selective decomplexation
    [0340] Preparation of the complex of formula (II)
    [0341] In a reactor, 90 kg (119 moles) of the hexaacid complex of formula (I) and 650 kg of methanol are charged. The mixture is cooled to approximately 0°C then 111 kg (252 moles) of a solution of methanolic hydrochloric acid (8.25% HCl in methanol) is poured in, maintaining the temperature at 0°C. The reaction medium is brought to room temperature and then kept under stirring for 16 hours. After cooling to 0-5°C, 120 kg (1319 moles) of 3-amino-1,2-propanediol are added. The reaction medium is then heated by distilling the methanol under vacuum until a temperature of 60-65°C is reached. The concentrate is maintained for 16 hours at this temperature under vacuum. At the end of contact, the medium is diluted with 607 kg of water while cooling to ambient temperature. The solution of the crude complex of formula (II) is neutralized with 20% (m/m) hydrochloric acid. 978.6 kg of solution are thus obtained, with a concentration of 10.3%, representing 101 kg of material. The yield obtained is 86.5%, the purity of the complex of formula (II) is 92.3% (HPLC s/s). The amount of decoupled impurities is 6.4% (HPLC s/s).
    [0342] Nanofiltration Purification of the complex of formula (II) Nanofiltration
    [0343] The nanofiltration membrane used has a cut-off threshold of 200 Daltons (Koch Membran System SR3D). This processing is carried out as follows:
    [0344] Traitement sur résines The crude complex solution of formula (II) is heated to 30°C. The nanofilter is filled with said solution. The pump is started first at low flow to purge the system, then the nanofilter pump flow is gradually increased to the desired recirculation flow (1.0 m 3 /h for a 2.5 X 40 inch membrane) . The system is then placed in total recirculation at 30° C. for at least 2 hours to establish a bias layer. The medium is then passed through diafiltration at 30° C. under 25 bars, keeping the volume constant by adding pure water until a conductivity of the retentate <1000 μS is obtained. At the end of diafiltration, the medium is concentrated until a concentration of approximately 40% (m/m) is obtained. Treatment on resins
    [0345] The complex solution of formula (II) resulting from nanofiltration is diluted with purified water with stirring to obtain a 15% (m/m) solution. This solution is eluted in series on 50 liters of strong anionic resins (FPA900) in the OH - form then on 50 liters of weak cationic resins (HP336) in the H + form at an average elution rate of 2V/V/H (2 volumes of solution per volume of resin per hour). The resins are then rinsed with approximately 450 liters of purified water until a refractive index of less than 1.3335 is reached.
    [0346] Ultrafiltration The complex solution of formula (II) is then concentrated by heating to 50-60° C. under a vacuum of 20 mbar to reach a concentration of 35% (m/m). Ultrafiltration
    [0347] The ultrafiltration membrane is a UF 10KD Koch Spiral membrane.
    [0348] Atomisation The ultrafilter is fed with the previous solution of complex of formula (II) at 35% heated to 40°C. Ultrafiltration is applied at a flow rate of 3m 3 /H with a transmembrane pressure of 2.5-3 bars. Several rinsings of the system with 13 liters of pyrogen-free purified water are carried out until a final dilution of the complex of formula (II) of 25% (m/m) is reached. Atomization
    [0349] The complex of formula (II) is obtained in powder form by atomization of the preceding solution of complex of formula (II) concentrated at 25%.
    [0350] Atomization is done as follows:
    [0351] The atomizer is balanced with pure, pyrogen-free water by adjusting the inlet temperature to 165°C – 170°C and adjusting the feed rate so that the outlet temperature is between 105 and 110°C.
    [0352] Then, the concentrated solution of complex of formula (II) is added and the flow rate is adjusted so as to maintain the above parameters.
    [0353] These operating conditions are maintained throughout the atomization, while ensuring the good behavior of the powder in the atomization chamber and at the outlet of the atomizer. In particular, it must be ensured that there is no sticking of the product.
    [0354] At the end of feeding the atomizer with the solution, the container of this complex of formula (II) and the atomizer are rinsed with pure, pyrogen-free water until maximum recovery of the powder.
    [0355] A complex of formula (II) which is 99.6% pure is obtained.
    [0356] This degree of purity was determined by reverse phase liquid chromatography.
    [0357] Composition according to the invention and results of studies thereon
    [0358] Example of manufacturing process according to the invention
    [0359] The process for manufacturing a composition according to the invention is carried out by following the following steps:
    [0360] a) 485.1 g (i.e. 0.5 M) of complex of formula (II) is dissolved in water (qs 1 litre) by heating the tank to a temperature between 39 and 48° C. and carrying out a strong agitation of the solution until complete dissolution of this complex in water. The solution is then cooled to about 30°C.
    [0361] b) 0.404 g (i.e. 0.2% mole/mole relative to the proportion of complex added in step a)) of DOTA (Simafex, France) is added with stirring to the solution obtained in step a) via a 10% w/v DOTA solution.
    [0362] c) Trometamol (Tris) is added to the solution obtained in step b) with stirring. The pH is then adjusted to a value between 7.2 and 7.7 by adding a hydrochloric acid solution with stirring.
    [0363] d) The targeted concentration (0.5 mol/L) is obtained by adding water in two steps for the injection until a density value between 1.198 and 1.219 g/mL is obtained.
    [0364] The liquid composition is then filtered through a polyethersulfone membrane and placed in its final container, which is finally subjected to sterilization at 121° C. for 15 minutes.
    [0365] Example of composition in accordance with the invention
    [0366] Thanks to the process described above, the following formulation is obtained: Ingredients Proportions in the compositionComplex of formula (II) 485.1g (0.5M)DOTA** 0.404 g (1 mM or 0.2% mol/mol vs complex)NaOH or HCl Qs pH 7.2 to 7.7Trometamol 1.211gFree gadolinium* < 1ppm m/vWater for injection (ready for injection) Qs 1 L
    [0367] * Measured by colorimetric method with xylenol orange
    [0368] **expressed on an anhydrous and pure basis
    [0369] Formulation tests carried out (details not provided)
    [0370] Different concentrations of trometamol from 0 to 100 mM were tested. The results of these tests showed that a content of 10 mM (0.12% w/v) was sufficient to guarantee the stability of the pH of the formulation while limiting the formation of degradation impurities.
    [0371] Different concentrations of DOTA from 0 to 2.5 mM were tested. The results of these tests showed that a content of 1 mM, which corresponds to 0.04% m/v or 0.2% mol/mol, ensures the absence of free Gd release during the process and during product life.
    [0372] Stability studies under accelerated conditions of a composition according to the invention
    [0373] The formulation of the previous example is analyzed just after its manufacture (T 0 ) and after storage at 40° C. for 6 months after its manufacture (T+6 months).
    [0374] AT 0 :
    [0375] - Purity assessed by chromatography*: 99.6%
    [0376] - Gd-DOTA concentration: 0.007% (m/V)
    [0377] - Gd concentration: below 0.0001% (m/V)
    [0378] - pH: 7.5
    [0379] At T+6 months:
    [0380] - Purity assessed by chromatography*: 97.2%
    [0381] - Gd-DOTA concentration: 0.014% (m/V) - 0.25 mM
    [0382] - Gd concentration: below 0.0001% (m/V)
    [0383] - pH: 7.5
    [0384] * reverse phase liquid chromatography
    [0385] These results demonstrate that this formulation has good stability over time.
    权利要求:
    Claims (12)
    [0001]
    (II)constitué d’au moins 90 % d’un excès diastéréoisomérique comprenant un mélange d’isomères II-RRR et II-SSS de formules : (II-SSS), (II-RRR).Complex of formula (II) below: (II) consisting of at least 90% of a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers of formulas: (II-SSS),(II-RRR).
    [0002]
    Composition comprising the complex according to claim 1 and a free macrocyclic ligand, and advantageously having a free gadolinium concentration of less than 1 ppm (m/v).
    [0003]
    Composition according to Claim 2, characterized in that it comprises between 0.002 and 0.4% mol/mol of free macrocyclic ligand relative to the complex of formula (II).
    [0004]
    Composition according to Claim 2 or 3, characterized in that the free macrocyclic ligand is selected from the group consisting of DOTA, NOTA, DO3A, BT-DO3A, HP-DO3A, PCTA, DOTA-GA and their derivatives.
    [0005]
    Composition according to Claim 4, characterized in that the free macrocyclic ligand is 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA).
    [0006]
    (II)constitué d’au moins 80 % d’un excès diastéréoisomérique comprenant un mélange d’isomères II-RRR et II-SSS de formule : (II-SSS), (II-RRR)comprenant :1)la combinaison des 2 étapes suivantes :1b) passage sur résine(s) échangeuse(s) d’ions, et1c) ultrafiltration dudit complexe, et2)l’isolement du complexe purifié ainsi obtenu sous forme solide.Process for purifying the complex of formula (II) below: (II) consisting of at least 80% of a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers of formula: (II-SSS), (II-RRR) including: 1) the combination of the following 2 steps: 1b) passing over ion exchange resin(s), and 1c) ultrafiltration of said complex, and 2) isolation of the purified complex thus obtained in solid form.
    [0007]
    Process according to Claim 6, characterized in that stages 1b) and 1c) are additionally combined with a stage 1a) of nanofiltration.
    [0008]
    Process according to Claim 6 or 7, characterized in that steps 1a) when the latter is present, 1b and 1c are carried out in this order.
    [0009]
    Process according to any one of Claims 6 to 8, characterized in that stage 2) comprises atomization.
    [0010]
    (II)constitué d’au moins 80 % d’un excès diastéréoisomérique comprenant un mélange d’isomères II-RRR et II-SSS de formules : (II-SSS), (II-RRR),susceptible d’être obtenu par le procédé selon l’une quelconque des revendications 6 à 9.Complex of formula (II): (II) consisting of at least 80% of a diastereoisomeric excess comprising a mixture of II-RRR and II-SSS isomers of formulas: (II-SSS), (II-RRR), obtainable by the process according to any one of claims 6 to 9.
    [0011]
    Composition comprising the complex according to Claim 10 and free DOTA, and advantageously having a free gadolinium concentration of less than 1 ppm (m/v).
    [0012]
    Composition according to Claim 11, characterized in that it comprises between 0.002 and 0.4% mol/mol of DOTA relative to the complex of formula (II).
    类似技术:
    公开号 | 公开日 | 专利标题
    EP3943493A1|2022-01-26|Complex of gadolinium and a chelating ligand derived from diastereoisomerically enriched pcta and method for preparing and purifying same
    EP2988756B1|2017-03-08|Contrast medium formulation and related preparation method
    EP0835140B1|2001-10-31|Metal complexes of polyaminoacids, and their utilization in diagnostic imaging
    EP2982669B1|2017-05-10|Metal-ion chelating agents, methods for preparing same and uses thereof
    EP2429590B1|2020-04-22|Method for preparing a pharmaceutical formulation of lanthanide chelate
    WO2022013454A1|2022-01-20|Method for preparing a chelating ligand derived from pcta
    EP3936505A1|2022-01-12|Complex of gadolinium and a chelating ligand derived from diastereoisomerically enriched pcta and method for synthesising same
    US20210371437A1|2021-12-02|Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process
    US20210361782A1|2021-11-25|Complex of gadolinium and a chelating ligand derived of a diastereoisomerically enriched pcta and synthesis method
    BR112021014006A2|2021-09-21|GADOLINIUM COMPLEXES, COMPOSITIONS COMPRISING THEM AND PURIFICATION PROCESS
    FR2725449A1|1996-04-12|POLYAZACYCLOALCANES DERIVATIVES, THEIR METAL COMPLEXES AND PHARMACEUTICAL PRODUCTS INCORPORATING THESE COMPLEXES
    EP1648883B1|2017-08-30|Lanthanide complexes preparation and uses thereof
    BR112021014087A2|2021-09-21|GADOLINIUM COMPLEXES, PREPARATION PROCESS AND BUTYL HEXAESTER
    同族专利:
    公开号 | 公开日
    FR3091873B1|2020-12-25|
    CA3126268A1|2020-07-23|
    JP2022009463A|2022-01-14|
    AR117835A1|2021-08-25|
    EP3902800A1|2021-11-03|
    IL284884D0|2021-08-31|
    CN113735854A|2021-12-03|
    TW202043227A|2020-12-01|
    KR20210109039A|2021-09-03|
    SG11202107779SA|2021-08-30|
    CL2021001868A1|2022-01-21|
    EP3943493A1|2022-01-26|
    CN113646308A|2021-11-12|
    WO2020148436A1|2020-07-23|
    AU2020208794A1|2021-08-05|
    US20220062443A1|2022-03-03|
    KR20210138134A|2021-11-18|
    JP2022508496A|2022-01-19|
    CO2021009261A2|2021-12-10|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4647447A|1981-07-24|1987-03-03|Schering Aktiengesellschaft|Diagnostic media|
    US5876695A|1986-11-28|1999-03-02|Schering Aktiengesellschaft|Metal complex-containing pharmaceutical agents|
    EP0438206A1|1990-01-18|1991-07-24|Schering Aktiengesellschaft|6-Ring-containing macrocyclic tetraaza compounds, processes for their preparation, and pharmaceutical agents containing them|
    EP1931673A1|2005-10-07|2008-06-18|Guerbet|Compounds comprising short aminoalcohol chains and metal complexes for medical imaging|
    WO2014174120A1|2013-04-26|2014-10-30|Guerbet|Contrast medium formulation and related preparation method|
    JP2021533165A|2018-08-06|2021-12-02|ブラッコ・イメージング・ソシエタ・ペル・アチオニBracco Imaging S.P.A.|PCTA-based contrast agent|
    WO2022013454A1|2020-07-17|2022-01-20|Guerbet|Method for preparing a chelating ligand derived from pcta|
    法律状态:
    2020-01-27| PLFP| Fee payment|Year of fee payment: 2 |
    2020-07-24| PLSC| Publication of the preliminary search report|Effective date: 20200724 |
    2021-01-25| PLFP| Fee payment|Year of fee payment: 3 |
    2022-01-25| PLFP| Fee payment|Year of fee payment: 4 |
    优先权:
    申请号 | 申请日 | 专利标题
    FR1900432A|FR3091873B1|2019-01-17|2019-01-17|COMPLEX OF GADOLINIUM AND A LIGAND CHELATOR DERIVED FROM PCTA DIASTEREOISOMERICALLY ENRICHED AND PROCESS FOR PREPARATION AND PURIFICATION|
    FR1900432|2019-01-17|FR1900432A| FR3091873B1|2019-01-17|2019-01-17|COMPLEX OF GADOLINIUM AND A LIGAND CHELATOR DERIVED FROM PCTA DIASTEREOISOMERICALLY ENRICHED AND PROCESS FOR PREPARATION AND PURIFICATION|
    JP2021541202A| JP2022508496A|2019-01-17|2020-01-17|Gadolinium and chelate ligand complexes derived from diastereoisomerically enriched PCTA and preparation and purification processes|
    EP21190088.1A| EP3943493A1|2019-01-17|2020-01-17|Complex of gadolinium and a chelating ligand derived from diastereoisomerically enriched pcta and method for preparing and purifying same|
    EP20701709.6A| EP3902800A1|2019-01-17|2020-01-17|Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process|
    CA3126268A| CA3126268A1|2019-01-17|2020-01-17|Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process|
    KR1020217025766A| KR20210109039A|2019-01-17|2020-01-17|Complexes of chelating ligands derived from gadolinium and diastereomerically enriched PCTA, and processes for preparation and purification|
    US17/423,638| US20220062443A1|2019-01-17|2020-01-17|Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process|
    TW109101779A| TW202043227A|2019-01-17|2020-01-17|Diastereoisomerically enriched complex of gadolinium and of a pcta-based chelating ligand, and process for preparing and purifying same|
    KR1020217036451A| KR20210138134A|2019-01-17|2020-01-17|Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process|
    AU2020208794A| AU2020208794A1|2019-01-17|2020-01-17|Diastereoisomerically enriched complex of gadolinium and of a PCTA-based chelating ligand, and process for preparing and purifying same|
    PCT/EP2020/051153| WO2020148436A1|2019-01-17|2020-01-17|Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process|
    ARP200100125A| AR117835A1|2019-01-17|2020-01-17|GADOLINIUM ENRICHED DIASTEREOISOMERIC COMPLEX AND A PCTA-BASED CHELANT BINDER, AND PROCESS OF PREPARATION AND PURIFICATION OF THE SAME|
    CN202111049738.3A| CN113735854A|2019-01-17|2020-01-17|Complexes of gadolinium and chelate ligands based on diastereomer enriched PCTA and methods for their preparation and purification|
    CN202080009625.8A| CN113646308A|2019-01-17|2020-01-17|Complexes of gadolinium and chelate ligands based on diastereomer enriched PCTA and methods for their preparation and purification|
    SG11202107779SA| SG11202107779SA|2019-01-17|2020-01-17|Diastereoisomerically enriched complex of gadolinium and of a pcta-based chelating ligand, and process for preparing and purifying same|
    CL2021001868A| CL2021001868A1|2019-01-17|2021-07-14|Complex of gadolinium and a diastereomerically enriched pcta-derived chelating ligand and method of preparation and purification.|
    IL284884A| IL284884D0|2019-01-17|2021-07-15|Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process|
    CONC2021/0009261A| CO2021009261A2|2019-01-17|2021-07-15|Complex of gadolinium and a diastereomerically enriched pcta-derived chelating ligand and method of preparation and purification|
    US17/403,610| US20210371437A1|2019-01-17|2021-08-16|Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched pcta and preparation and purification process|
    JP2021173867A| JP2022009463A|2019-01-17|2021-10-25|Gadolinium and chelate ligand complexes derived from diastereomerically enriched PCTA and preparation and purification processes|
    [返回顶部]